SNTA1

Across TCGA pan-cancer cohorts, SNTA1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SNTA1 data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SNTA1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNTA1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

STAD, SKCM, and COAD are the cancer types where SNTA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.501	0.660	.006	16	view →
SKCM	OS	Median	II,III,IV	0.282	0.736	.002	12	view →
COAD	DFS	Median	All	0.424	0.798	.001	9	view →
BLCA	DFS	Median	All	1.000	0.327	.034	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.156	0.774	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SNTA1–STAD (OS)

Open the STAD breakdown →